OncoMatch/Clinical Trials/NCT06966024
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Is NCT06966024 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies DCC-2812 for renal cell carcinoma.
Treatment: DCC-2812 — This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Renal Cell Carcinoma
Urothelial Carcinoma
Prostate Cancer
Disease stage
Metastatic disease required
Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Prior therapy
Cannot have received: anticancer therapy
Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function and electrolytes
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber Cancer Institute · Boston, Massachusetts
- NEXT Oncology, Austin · Austin, Texas
- NEXT Oncology, San Antonio · San Antonio, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06966024 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anticancer therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify